News

May 20, 2019

Therapy for Heavily Treated Multiple Myeloma Gets Fast Track Status from FDA

News

Cellectar Biosciences’ candidate CLR 131 received Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma patients who have failed at least ... Read more

May 17, 2019

Revlimid and Imnovid Triple Combos Approved in EU for Adults with Multiple Myeloma

News

The European Commission has approved two combination therapies based on Celgene‘s Revlimid (lenalidomide) and Imnovid (pomalidomide), added to Velcade (bortezomib) and dexamethasone, for the treatment of some adult patients with multiple myeloma. ... Read more

May 15, 2019

Takeda Oncology Launches Myeloma Patient and Caregiver Mentorship Support Program

News

Takeda Oncology has launched a mentorship program aimed at empowering and encouraging multiple myeloma patients and caregivers throughout their disease journey. Called My Mentor Connections, the program enlists caregivers ... Read more

May 13, 2019May 13, 2019

Phase 3 Trial of Immune System-targeting Treatment for Advanced Multiple Myeloma Begins Dosing

News

A pivotal Phase 3 clinical trial has begun dosing participants to evaluate MorphoSys‘s investigational antibody, MOR202 (TJ202), in combination with Revlimid (lenalidomide) plus dexamethasone, for the treatment of relapsed ... Read more

May 10, 2019

OncLive Poised to Induct 2019 Class of ‘Giants of Cancer Care’

News

OncLive, a digital resource platform for oncologists, will welcome 15 new members at its 7th Annual Giants of Cancer Care Winners Reception on May 30 in Chicago, Illinois. Inductees are ... Read more

May 8, 2019

Allogene’s CAR T-cell Therapy Triggers Durable Anti-Tumor Response in Animal Model

News

ALLO-715, Allogene Therapeutics‘ donor-derived CAR T-cell therapy, can trigger a durable anti-tumor response in mice with multiple myeloma, and maintain its characteristics and anti-tumor activity after large-scale manufacturing, a study ... Read more

May 6, 2019

Kyprolis Combo Shows Promise for Newly Diagnosed, Transplant-eligible Patients

News

A triple regimen composed of Kyprolis (carfilzomib), thalidomide, and dexamethasone, given before and after high-dose chemotherapy and autologous stem cell transplant, is safe and highly effective for the treatment ... Read more

May 1, 2019

bluebird bio Opens Manufacturing, Research Facility in Durham, N.C.

News

Bluebird bio has officially opened a facility in Durham, North Carolina, to make the lentiviral vector needed for its investigational gene and cell treatments, including the CAR T-cell therapies bb2121 and bb21217 ... Read more

April 29, 2019

Ninlaro Maintenance Therapy Prolongs and Boosts Treatment Benefits in Myeloma Patients, Study Says

News

Maintenance therapy with Ninlaro (ixazomib) can prolong and boost therapeutic responses from initial treatment in multiple myeloma patients who did not undergo an autologous stem cell transplant, a study says. The ... Read more

April 26, 2019

ChemioCare Developing New Lenalidomide Skin Patch

News

Aiming to improve lenalidomide‘s safety and efficacy, ChemioCare is setting up to develop a new treatment formulation delivered through a skin patch, maintaining an optimal blood level of the medicine ... Read more

Pin It on Pinterest